MyeloRx is
a development company advancing a portfolio of triptolide-based compounds through
IND-enabling pre-clinical studies.
Because the natural product triptolide itself as well as the herb from
which it was derived has shown unequivocal clinical activity we believe the
clinical risk is relatively low. We are
focusing on proprietary prodrugs and derivatives of the natural product
triptolide for oncology and immune-diseases.
Triptolide is functionally similar to rapamycin (Rapamune®) and
paclitaxel (Taxol®, Taxotere®), two approved natural products, in that each of
these has anti-cancer and immune suppressant properties, however, triptolide
has a different mechanism of action.